Neurogene to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Neurogene Inc. (NASDAQ: NGNE) announced its participation in upcoming investor conferences to discuss its genetic medicines for rare neurological diseases. Management will engage in various formats at TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Stifel 2024 Virtual CNS Days.

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following investor conferences:

TD Cowen 44^th Annual Health Care Conference
Format: Management will participate in a CNS Corporate Panel and investor meetings
Date: Tuesday, March 5 at 10:30 a.m. ET

Leerink Partners Global Biopharma Conference
Format: Management will participate in investor meetings
Date: Monday, March 11

Stifel 2024 Virtual CNS Days
Format: Management will participate in a fireside chat
Date: Wednesday, March 20 at 9:30 a.m. ET

Live webcasts of the panel and fireside chat can be accessed from the Investor Relations section of Neurogene’s website under events, where a replay of the events will also be available for a limited time.

About Neurogene

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and by designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit www.neurogene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240229815231/en/

Neurogene Contacts:

Investor Relations:

Melissa Forst

Argot Partners

Neurogene@argotpartners.com



Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

Source: Neurogene Inc.

FAQ

When will Neurogene participate in the TD Cowen 44th Annual Health Care Conference?

Neurogene will participate on Tuesday, March 5 at 10:30 a.m. ET in a CNS Corporate Panel and investor meetings.

What is the format of Neurogene's participation in the Leerink Partners Global Biopharma Conference?

Neurogene's management will engage in investor meetings on Monday, March 11.

When is Neurogene set to participate in the Stifel 2024 Virtual CNS Days?

Neurogene will participate on Wednesday, March 20 at 9:30 a.m. ET in a fireside chat.

Where can the live webcasts of Neurogene's panel and fireside chat be accessed?

The live webcasts can be accessed from the Investor Relations section of Neurogene’s website under events, with a replay available for a limited time.